Sana Biotechnology Inc
$ 3.52
3.23%
07 Aug - close price
- Market Cap 979,586,000 USD
- Current Price $ 3.52
- High / Low $ 3.54 / 3.41
- Stock P/E N/A
- Book Value 0.44
- EPS -0.92
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -1.47 %
- 52 Week High 6.55
- 52 Week Low 2.61
About
Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
Analyst Target Price
$8.57
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-10 | 2026-05-11 | 2026-03-03 | 2025-11-06 | 2025-08-11 | 2025-05-08 | 2025-03-17 | 2024-11-08 | 2024-08-08 | 2024-05-08 | 2024-02-29 | 2023-11-08 |
| Reported EPS | None | -0.14 | -0.16 | -0.15 | -0.16 | -0.2 | -0.23 | -0.27 | -0.32 | -0.32 | -0.41 | -0.41 |
| Estimated EPS | -0.15 | -0.15 | -0.1444 | -0.19 | -0.21 | -0.2 | -0.2428 | -0.27 | -0.24 | -0.22 | -0.38 | -0.45 |
| Surprise | 0 | 0.01 | -0.0156 | 0.04 | 0.05 | 0 | 0.0128 | 0 | -0.08 | -0.1 | -0.03 | 0.04 |
| Surprise Percentage | None% | 6.6667% | -10.8033% | 21.0526% | 23.8095% | 0% | 5.2718% | 0% | -33.3333% | -45.4545% | -7.8947% | 8.8889% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.15 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SANA
2026-08-09 13:09:31
Sana Biotechnology Inc. is set to report its second-quarter results on Monday, with analysts expecting a narrower loss of 15 cents per share and no revenue. Investors will be closely watching for updates on its in vivo CAR-T platform, specifically SG293, and its stem cell-derived islet cell therapy SC451, as well as the company's cash burn and financing plans. The stock has a "strong-buy" rating from Wall Street, with an implied upside of 143% from its current trading price.
2026-08-08 08:12:07
Sana Biotechnology Inc (SANA) has a target price of USD 7.00, with analysts forecasting a potential upside of 151.36%. Based on ratings from 9 analysts, the consensus for SANA stock is a "Buy." The company's EPS for the previous quarter was USD -0.21, and the next quarter is expected at USD -0.15.
2026-08-04 08:12:07
Sana Biotechnology (SANA) is expected to report its Q2 2026 earnings on Monday, August 10th, with analysts projecting a loss of $0.1469 per share. The company's shares opened at $3.08, and its market capitalization is approximately $858 million. Analyst sentiment is mixed but leans positive, with an average price target of $9.50 and institutional investors owning 88.23% of the stock.
2026-07-30 04:40:22
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Sana Biotechnology, Inc. (NASDAQ: SANA) breached their fiduciary duties to shareholders. The firm encourages long-term Sana shareholders to contact them to discuss legal options, including seeking corporate governance reforms or the return of funds to the company. They operate on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees.
2026-07-28 03:40:42
This article provides a detailed cash flow statement for Sana Biotechnology Inc (SANA), including quarterly and annual data for operating, investing, and financing activities. It presents key financial metrics such as net income, capital expenditures, and free cash flow, alongside year-over-year percentage changes. The article also includes a FAQ section defining different types of cash flow and their significance for investors.
2026-07-27 21:11:59
This article provides a detailed financial overview of Sana Biotechnology Inc (SANA), including its stock price, market cap, and key financial indicators. It presents current and historical data for income statements, balance sheets, and cash flow statements, along with recent earnings reports and analyst ratings. The report highlights the company's EPS, net profit, assets, liabilities, and equity, offering insights into its financial health over various quarters and fiscal years.
